Upload
lelien
View
223
Download
0
Embed Size (px)
Citation preview
Digital Therapeutics in the NHS:The rise of digital therapies & the evidence that proves they work
#DHLCOLLABORATE
#DigitalHealthLondon
Tuesday, 24 April 2018
Dr Mark Davies
Event chair
GP, Non-Executive Director – BMJ, Chair of Clinical Advisory Board -Your.MD
Definition:Digital therapeutics, a subset of digital health, is a health discipline and treatment option that utilizes a digital and often online health technologies to treat a medical or psychological condition. The treatment relies on behavioural and lifestyle changes usually spurred by a collection of digital impetuses
Source: Wikipedia
Time Item Speakers
13:20pm Welcome & Introduction Dr Mark Davies, GP, Non Exec Director -BMJ, Chair of Clinical Advisory Board - Your.MD
13.30pm Setting the Scene Dr Indra Joshi, Clinical Lead, NHS England
13.45pm ‘World class Digital Therapeutics’ and their growing value in the UK
What is a /Digital Therapeutic’? And what does a good one look like?
Murray Aitken - Executive Director, IQVIA
Nelia Padilla - Vice President Digital Health Strategy, IQVIA
14.30pm Panel: Interrogating the evidence Neelam Patel - COO, MedcitySimon Dixon - Head of Digital Health Strategy, Public Health EnglandOn the sofa with: Voluntis, myCOPD, Akili, Welldoc, Sleepio
15.15pm Coffee Break
15.30pm Toward a more digitally enabled research world in the NHS and NIHR
Dr Jonathan Sheffield - CEO, NIHR Clinical Research Network (CRN)
16:00pm Have Your Say: Rapid fire table top discussion
16.15pm Audience Question Time: Shaping a digital therapies toolkit
Chair: Sarah Haywood - CEO, MedCityPanel: Dr Indra Joshi - Clinical Lead - NHS England Mark Duman – North West Service Champion - Diabetes UKProfessor Martin Cowie - Professor of Cardiology Royal Brompton and Harefield NHS Foundation Trust Dr Mark Kelsey - GP, Clinical Chair, Southampton City CCG, Mark Campbell - Acting Programme Director, National Institute for Health and Care ExcellenceProfessor Colin Espie Co-Founder and Chief Medical Officer at Big Health
17.15pm Closing thoughts & reflections of the afternoon. Mark Campbell – Acting Programme Director, NICE
Yinka Makinde – Programme Director, DigitalHealth.London
17.30pm Networking and refreshments
19.00pm Event close
4
Copyright © 2018 IQVIA. All rights reserved.
Digital Therapeutics in the NHS
April 24, 2018
Murray Aitken, Executive Director, IQVIA Institute
The Growing Value
of Digital Health
8
3RD REPORT BY
INSTITUTE RELATED TO
DIGITAL HEALTH
• October 2013: Patient Apps
for Improved Healthcare:
From Novelty to Mainstream
• September 2015: Patient
Adoption of mHealth:
Use, Evidence and
Remaining Barriers to
Mainstream Acceptance
CONTENTS
• Proliferation of digital
health tools
• Innovative uses of sensors
• Delivering value to patients and
the health system
• Investments in evidence
• Accelerating use
in medicine
IQVIA Institute Research
HIMSS18 Belgian Delegation
9
Number of consumer health apps has nearly
doubled since 2015: 318,500 now available
with about 200 new apps added daily to top
app stores
• Apps focused on health conditions and patient care now
about for 40% of all apps, up from 27% in 2015
• Increased number of sensors now available bringing new
health uses, and consumer satisfaction with apps is
increasing
• Use of apps extend across the entire patient journey
• Validation of digital biomarkers and digital therapeutics
portend more extensive uses of apps and other digital
health tools
Growing confidence in the value patients,
providers, payers and overall health system
can receive from appropriate use of digital
health tools
• Clinical evidence of Digital Health efficacy has grown
substantially: 571 studies published with over a quarter
released in 2017
• Evaluation/curation platforms can provide guidance to
healthcare professionals
• Health-related apps in five therapy areas could reduce
total healthcare costs by 1-2% ($7 billion in annual
savings in U.S.; GBP170 million in UK)
• Investment in evidence development is high: 860 clinical
trials currently underway with 82% of U.S. trials run by
patient care organizations
Key Findings
HIMSS18 Belgian Delegation
▪ mHealth space is maturing, though still faces some major barriers
10
Digital Health Tools
Source: IQVIA Institute, Sep 2017
HIMSS18 Belgian Delegation
Personal Health
Records
Consumer
Wearables
Web-based
Interactive Programs
Smartphone
Cameras
Health System Disease
Management Apps
Text Messaging
or Email
Connected Biometric
Sensors
Consumer
Mobile Apps
Clinical Trial
Patient Information
Collection Tools
DIGITAL HEALTH
Telemedicine and
Virtual Physician Visits
In-Home Connected
Virtual Assistants
11
Digital Health in the Patient Journey
Source: IQVIA AppScript Use Categories. IQVIA Institute, Sep 2017
HIMSS18 Belgian Delegation
Wellness & Prevention
• Exercise & Fitness
• Diet & Nutrition
• Lifestyle & Stress
• Stress Management
• Sleep/Insomnia
• Smoking Cessation
• Alcohol Moderation
Wellness &
Prevention
DiagnosisSymptom Onset
and Seeking Care
Condition
MonitoringTreatment
Patient Experience Tools
• General Healthcare
Information
• Symptom Checking
• Finding a Clinician
• Managing Clinical and
Financial Information
• Social Media
Physician may recommend
app-supported disease
management programs,
connected sensors for remote
monitoring, or apps for any use
case across the patient journey
Condition Education &
Management
• Self-Monitoring
• Remote Patient Monitoring
• App-Enabled Rehabilitation
Program
Prescription Filling &
Compliance
• Prescription Discounts
• Prescription Filling
• Medication Management &
Adherence
= Digital Health Use Categories= Patient Journey
12
Number of Published Digital Health Efficacy & Effectiveness Studies
Source: AppScript Clinical Evidence, August 14 2017
Notes: Analysis excludes accuracy stDatabaseudies. Only includes studies with hard outcomes. ‘Observational Study’ includes all trials examining interventional value or impact of an app excluded from the other
three categories regardless of design.
HIMSS18 Belgian Delegation
0
20
40
60
80
100
120
140
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 YTD
Meta-analysis Systematic Review or Critically Appraised Topics Randomized Controlled Trial Observational Study
Total: 571 Efficacy Studies Between 2007-2017 (YTD)
13
Sources: IQVIA AppScript Clinical Evidence Database, Aug 2017
Notes: Only includes studies that evaluated the interventional value of a digital health solution (mobile or web app, connected device, or other mobile intervention such as texting) on patient outcomes such as
activity levels, lab results, or healthcare resource utilization. Average of study results for the highest quality evidence available (i.e., meta-analysis > RCT > Observational)
HIMSS18 Belgian Delegation
Maturity of Digital Health Efficacy Studies by Use Category, 2017
Cumulative #
of Efficacy
Studies
LIMITED Relative Quantity & Quality of Available Clinical Evidence
Notable
NOTABLE
General Lack of Studies
Potential Disappointments – More Study Required
• GI Conditions• Self-Diagnosis &
Symptom Checking• Finding an HCP• Managing Clinical
and Financial Records
• Medication Discounts
• Pregnancy• Well Newborn• ADHD• Hyperlipidemia• Epilepsy
• Pneumonia• Vision • Oral Diseases• General HC Info• Social Media
• Exercise• Pain Management
• Dermatological Conditions• Schizophrenia / Bipolar
• Multiple Sclerosis• Autism
Candidates for
Inclusion in Clinical
Guidelines
• Diabetes• Depression• Anxiety
Candidates for
Evaluation in an RCTALL POSITIVE
• AF Screening• Medication Refills• MI• Hematology• Dental
One
Observational
Study
No StudiesMultiple
Observational
Studies
One RCT
Study
Multiple RCT
Studies
One
Meta-analysis
Multiple
Meta-analysis
Studies
ALL NEGATIVE
Ave
rag
e S
tud
y R
es
ult
s*
• Healthy Eating / Weight Management• Asthma• Infectious & Parasitic Disease• COPD• Hearing Loss & Tinnitus• CHF• Stroke• Alzheimer’s Disease
• Medication Management• Alcohol & Substance Abuse• Sleep / Insomnia• Cancer• Smoking Cessation• Parkinson’s Disease• Hypertension• Cardiac Rehab
• Stress Management• Alcohol Moderation• PTSD• Genitourinary Conditions• Diabetes Prevention• Arthritis• Kidney Disease• Pulmonary Rehab
Candidates for Adoption
14
DiabetesPrevention
Diabetes Asthma PulmonaryRehab (COPD)
Cardiac Rehab(MI)
TOTAL
Reduced Emergency Hospitalisation Costs Reduced A&E Costs Reduced Ambulatory Costs Reduced Drug Costs Other Intervention Cost
The Growing Value of Digital Health:A Roundtable Discussion of the Institute Report
Clinically-validated apps also have economic value to the NHS
Source: IQVIA AppScript Essentials Value Model, Aug 2017 (data on file)
Key Assumptions
• Use of 5 Curated Apps used
in 5 underlying studies suggesting acute
care utilization benefits
• Delivery to each target patient for the
given use case (but not necessarily used
by patient)
• No “Spill Over” Benefits to
other conditions (i.e., no reduced
healthcare utilization for stroke based on
improved blood sugar control in diabetics)
15
Fraction of AppScript Essentials that meet requirements
Clinicians’ requirements for prescribing apps
The Growing Value of Digital Health:A Roundtable Discussion of the Institute Report
Acceptable
Clinician
Workflow &
Usability
Accuracy,
Efficacy
and Safety
Data Privacy/
Security
Assurances
Mitigation of
Malpractice
Risk
Acceptable
Financial
Incentives
Patient
Usability
Most AllFew A Significant NumberNone
Wellness &
Prevention
Condition
Management
Emerging Accelerators of Adoption
Clinician
Adoption
To-Date
Interoperability
Standards
App Curation
Platforms
Merit-Based
Incentives
Potential
Inclusion in
Standard of
Care
Guidelines
Privacy/
Security
Guidelines
Permitted
Marketing
Claims
Source: American Medical Association, Digital Health Study, Sep 2016; IQVIA Institute Analysis, Sep 2017
Little
Little
16
The UK has made progress in creating an environment where clinically validated digital health apps can begin to succeed
NHS Apps
Library
Digital
Assessment
Questions (DAQs)
Initial
Endorsements
(Deprexis)
GP SoC
Framework
Potential
Gap
Potential
Gap
NHS Digital NHS Digital NICE NHS Digital
GP SoC: General Practitioner Systems of Choice Programme
17
3%
97%
Global VC Investment in Digital Health 2017(1)
UK Other
8%
92%
Global Digital Health Efficacy Study Publications 2007- Present(2)
UK Other
UK Other
However, the UK is not yet a leader in Digital Health
Source:
(1) Marc Sluijs. DIGITALHEALTH.NETWORK. 2017.
(2) AppScript Clinical Evidence Database
18
Opportunity in Real World Research: What if it was easier to do Digital Therapeutics studies in the UK?
51
Ability to
Immediately
Transition to Use
in Routine Care
Bench of Qualified
Independent
Research Teams to
produce high quality
research
publications
Pre-Contracted
“Digital
Therapeutics
Research
Network”
Simplified Study
Application &
Setup
2
4
App Prescribing
Platform &
3rd Party Research
Apps
that enables
patients to donate
their data
3
19
Too Informal
Bad Data
Just Right
Effectiveness Evidence
Too Formal
Efficacy Evidence
Examples • Marketing case studies
• App data published
directly
• Pragmatic RCTs conducted in
patients and sites similar to
likely use
• Certain Traditional RCTs
that leverage patients and
sites that are not similar to
likely use
Affordable
Good Science: Stands
up to Independent Review
Reproducible in Real
World
Outcome • Too much data
• Data may not be
predictive of value
• Sufficient evidence
• Evidence is reliably predictive
of value
• Not enough evidence
• Evidence may not be
predictive of value
Clinical Evidence Standards:Embracing the Digital Therapeutics “Goldilocks Principle”
Requirements
? ?
Copyright © 2018 IQVIA. All rights reserved.
Digital Therapeutics in the NHS
April 24, 2018
Murray Aitken, Executive Director, IQVIA Institute
The Growing Value
of Digital Health
Copyright © 2017 IQVIA. All rights reserved.
And What Does a Good One Look Like?
Nelia Padilla
Global Digital Health Lead
Consulting Services
IQVIA
What is a Digital
Therapeutic?
24
Yet, because something qualifies as a digital health, it does not mean it is a digital therapeutic – so what is a digital therapeutic?
Sources: https://en.wikipedia.org/wiki/Digital_therapeutics, https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/exploring-the-potential-of-digital-therapeutics, https://itunes.apple.com/us/podcast/a-healthy-
dose/id1197975925?mt=2&i=1000408238252,
Digital Therapeutics in the NHS Summit
If you trust Wikipedia, it’s:
“a subset of digital health, is a health discipline and treatment option
that utilizes a digital and often online health technologies to treat
a medical or psychological condition.”
OR
If you trust the CEO’s of self-labeled digital therapeutics firms, it’s:
A combination of software / technology used by patients that treats /
impacts disease
25
Importantly, Digital Therapeutics (DTx) represent a new way for the NHS to address improved clinical outcomes for its patients
In an ideal world, outcomes matter more than the product used
Types of Products for NHS Patients
• Increase lifespan
• Improve quality of life
• Cure disease
Clinical
Outcomes
Digital Therapeutics in the NHS Summit
Devices
Drugs
Digital
Therapeutics
26
What does a good digital therapeutic look like?
Digital Therapeutics in the NHS Summit
Demonstrated
Cost-Effectiveness
Regulatory Clearance
Incorporation into
Standard of Care
Intended Use
Demonstrated Efficacy
Digital Therapeutics (DTx) Maturity Criteria
1
2
3
4
5
27
The maturity of a DTx can be evaluated against these criteria
Digital Therapeutics in the NHS Summit
Treats
Non-Serious
Condition
Clearance
Req’d, Not
obtained
Regulatory
Clearance or
CE Mark
Cleared
Effectiveness
Claims
Regulatory Clearance
3
Informs
Treatment
Treats
Serious
Condition
Treats
Critical
Condition
Intended Use(1)
1
No
Studies
RCT or Other
Well-Controlled
Study
Lit
Review
RCT + Real-
World EvidencePilot /
Case
Study
Obs
Study
Demonstrated Efficacy
2
No
Incorporation/
Acceptance
Recommendation for
some digital
assistance
Recommendation
for specific digital
product type
Incorporation into
Standard of Care
4
Clearance Not
Required
Demonstrated Cost-
Effectiveness No Studies Non-published
Models
Real World
Cost of Care Study
5
Peer Reviewed
Models
(1) Derived from IMDRF. “Software as a Medical Device”: Possible Framework for Risk Categorization and Corresponding Considerations
Potential
“Read Across”
from Clinicals
28Digital Therapeutics in the NHS Summit
-2.5
-2.0
-1.5
-1.0
-0.5
0.0
0.5
1.0
1.5
2.0
% D
ecre
ase in A
1C
Valu
es O
ver
12 M
onth
s
0.7%-1.9%
PlaceboBlueStar
95% CI (1.5 – 2.3) (0.3 – 1.1)
Decrease in A1C Levels Over 12 Months for BlueStar vs. Control
Source: Quinn CC, Shardell MD, Terrin ML, Barr EA, Ballew SH, Gruber-Baldini AL. Cluster-randomized trial of a mobile phone
personalized behavioral intervention for blood glucose control. Diabetes Care. 2011;34(9):1934-1942. doi:10.2337/dc11-0366.
Study Design: Cluster-randomized clinical trial comparing A1C levels for patients using BlueStar intervention
vs. patients in control group
MEMBER
29Digital Therapeutics in the NHS Summit
-1.5
-2.0
-1.5
-1.0
-0.5
0.0
0.5
1.0
1.5
Improvement in A1C Control (# of points; p=0.0017)
40%
20%
PlaceboInsulia
Decrease in A1C after 4 Months with Insulia Percent of Patients Achieving 7% A1C
Target
Source: A. Daoudi, et al., A Smartphone for adjustment of basal insulin dose and for coaching: benefits in terms of glycaemic control for
type 2 diabetes patients. Poster presentation, EASD 2013
Study Design: Randomized clinical trial with 190 patients comparing improvement in A1C levels for patients on
Insulia intervention vs. placebo
MEMBER
30Digital Therapeutics in the NHS Summit
Source: Akili Interactive. Press Release. 2017.
Study Design: Multi-center, randomised, double-blind, active-controlled study in 348 children diagnosed with ADHD
AKL-T01MEMBER
31Digital Therapeutics in the NHS Summit
% P
art
icip
ants
Sle
ep E
ffic
iency >
80%
,
(% T
ime
in
be
d s
pe
nt a
sle
ep
)
Sleepio vs. Placebo and TAU
% Achieving healthy patterns, Sleep efficiency >80%
Study Design: Randomized, placebo-controlled trial measuring sleep efficiency of 164 adults across 3 arms:
cognitive behavioral therapy, imagery relief therapy (IRT: placebo), treatment as usual (TAU).
Source: Espie, Colin A et al. A Randomized, Placebo-Controlled Trial of Online Cognitive Behavioral Therapy for Chronic Insomnia
Disorder Delivered via an Automated Media-Rich Web Application. Sleep. 2012 Jun 1; 35(6): 769–781..
Placebo Treatment as
usual
In-person CBT-I
(benchmark data)
76%
29%
18%
70-75%
32Digital Therapeutics in the NHS Summit
433.6
388.7
445.1416.5
0
50
100
150
200
250
300
350
400
450
6 M
inu
te W
alk
Te
st D
ista
nce
(M
ete
rs)
+6.9%
+11.6%
Post-Intervention 6MWT DistanceBaseline 6MWT Distance
Face-to-Face InterventionMyCOPD
The adjusted mean difference for the 6MWT between groups demonstrated non-inferiority of the MyCOPD intervention
6 Minute Walk Test Distance for MyCOPD vs. Face to Face Intervention
Source: Bourne S, DeVos R, North M, Chauhan A, Green B, Brown T, Cornelius V, Wilkinson T. Online versus face-to-face pulmonary
rehabilitation for patients with chronic obstructive pulmonary disease: randomised controlled trial. BMJ Open. 2017
Study Design: Two-arm parallel single-blind, randomized controlled trial with 90 patients comparing 6 minute
walk test distance pre and post intervention with MyCOPD vs. face to face intervention
33
The panelists skew towards maturity, particularly on efficacy
Digital Therapeutics in the NHS Summit
Treats
Non-Serious Condition
Clearance Req’d,
Not obtained
Regulatory Clearance
or CE Mark
Cleared
Effectiveness Claims
Regulatory Clearance
3
Informs
Treatment
Treats
Serious Condition
Treats
Critical Condition
Intended Use(1)
1
No
Studies
RCT or Other Well-
Controlled Study
Lit
Review
RCT +
RWE
Pilot /
Case Study
Obs
Study
Demonstrated Efficacy
2
No Incorporation/
Acceptance
Recommendation for
some digital assistanceRecommendation for
specific digital product
type
Incorporation into
Standard of Care
4
Clearance Not
Required
Demonstrated
Cost-Effectiveness
5
(1) Derived from IMDRF. “Software as a Medical Device”: Possible Framework for Risk Categorization and Corresponding Considerations
*
* Akili’s product, EVO has been submitted to the FDA for regulatory clearnace
No Studies Non-published
Models
Real World
Cost of Care Study
Peer
Reviewed
Models
Potential
“Read Across”
from Clinicals
34
Please welcome today’s panelists
Anand Iyer,
Chief Strategy
Officer
Photo
Vincent
Hennemand,
VP of Strategy,
Corporate, & BD
Photo
Sophie Bostock,
UK Innovation
Lead, Big Health
Photo
Simon Bourne,
CEO, My mHealth
(Developer of
MyCOPD)
Photo
Pierre Leurent,
CEO, Voluntis
(Developer of
INSULIA)
Photo
Panel- Pierre Leurent, CEO, Voluntis
- Simon Bourne, CEO, My mHealth
- Sophie Bostock, UK Innovation Lead, Big Health
- Vincent Hennemand, VP of Strategy, Corporate, & BD, Akili
- Anand Iyer, Chief Strategy Officer at WellDoc, Inc. Chaired by:
Neelam Patel, COO, MedCity
Simon Dixon, Head of Digital Strategy, Public Health England
36
Dr Jonathan Sheffield, OBECEO of the National Institute for Health Research, Clinical Research Network
Towards a more digitally
enabled Research world in the
NHS and NIHR
Dr Jonathan Sheffield, Chief Executive Officer
NIHR Clinical Research Network
Demonstration by:
Mick Mullane, Digital Innovation Lead, National Institute for
Health Research (NIHR)
The demand for health and social care will continue to grow as the
population ages, co-morbidities become more common, and the
trend to personalised medicine continues.
In response, NIHR needs to develop life-changing treatments
faster in an environment of rising expectations amongst the public
and increasing pressures on health and social care. This requires
us to:
• Deliver a more personalised experience for the public to take
part in research at every step of the journey,
• Attract, support and grow the best health and care
researchers,
• Ensure that NIHR funded research improves the quality of
health and care for patients and the public,
• Work with our customers (Life Sciences industry and
charities) to maximise impact and benefit for all,
• Provide world-class research facilities.
The issue is made more urgent due to uncertainties surrounding
how industry and other funders will react to Brexit, creating new
opportunities for the UK’s role in Life Sciences.
The NIHR needs to deliver these changes quickly so that we meet
the growing healthcare needs of the nation.
Digital has transformed other industries, but has had a limited
impact on research across health and social care.
So we needed to work out how digital can help solve these
challenges...* National Cancer Patient Experience Survey 2015, National Results Summary# Patient Experience Survey Pilot, NIHR CRN
Growing demand: population aged 85+
Patients want to be involved
1992 2015 2033
82% 73% 77%said they’d
participate in
further surveys
about health
research*
would
recommend
taking part in
research to
friends & family#
would definitely
participate in
further research
studies#
Meeting the growing health and
care needs of the nation
We engaged with over 200 stakeholders to help us
understand what Digital meant for the NIHR and to
build real momentum for a transformational digital
strategy
We ran focus groups, interviews & online surveys to gather stakeholders’ views about the changes they would like to see
& how digital can help. Involving patients & the public at every step of the journey to ensure a strategy is designed which
meets their needs. Stakeholders are excited about the impact digital could have on how we do research and want to
continue working with us to make it happen.
Patients &
the Public#
NIHR
RegulatorsMHRA, HRA
Local
AuthoritiesSocial Care
ResearchersCharities &
public
funders
NHS
EnglandNHS Digital,
NHSI etc.
Life
Sciences
Industry*
#92 engaged during the process
*Life Sciences Industry includes pharma, medtech, biotech, diagnostic, contract research organisations etc.
Engaging with stakeholders across the health & care system Involving stakeholders from across the country
From the PATIENTS & THE PUBLIC About DATAFrom the RESEARCH COMMUNITY
“Awareness (of research) in the general public is very low and there is no
understanding that you have a choice”
“I am committed to research but I had questions and uncertainties about the study and there was no one to ask. So I
decided not to bother”
“If you gave me some great content, slides and videos, I would talk about research at
the Women’s Institute”
“If you want to reach us younger people, you need to use social [media]”
“Didn’t receive feedback during the trial therefore it was de-motivating and the
burden became more significant…”
“Research can be a lonely and frightening experience for patients”
“My heart sinks when I need to go back through the application process, confused with the offer of more help I don’t know
what different parts of the NIHR could do for me. I just see it as more forms to fill in”
“We don’t know where to start or who they should talk to within the NHS.
Knowing what research is going on is mainly the result of who you know”
“Approval occurs at local level. It would be much better to do this at national
level”
“We can’t see the whole research portfolio…you either get a twig or the
whole forest”
“Difficulties in accessing routine data…Difficulties in gaining
approvals…challenges facing recruitment…are all key obstacles to
research”
“You trust your data in the NHS. If you take part in an NHS branded study then you know your data isn’t going anywhere”
“Seamless systems and quick turnaround times would make UK the most attractive
place to do research”
“We need new digital skills if we want to do research in new ways”
“Information governance departments get nervous about data. Patients don’t have
massive hang-ups and we block it”
• Patients & the Public are rarely thanked for
taking part, making them feel disengaged
• Low awareness of the different opportunities
that exist to get involved in research
• Information required to make an informed
decision is not readily available
• Researchers processes are complex,
fragmented and time consuming
• Navigating the health & social care system
is difficult for the research community
• Establishing local agreements is a time
consuming & labour intensive process
• Gaining access to data is challenging, time
consuming and costly
• Patients are happy and want to share their
data
• The skills and tools to handle data etc. are
lacking across the health research system
Evid
en
ce
Con
clu
sio
ns
Stakeholder feedback
Develop and implement
five strategic digital services
Five strategic digital services to help
deliver better outcomes for patients &
the public across UK health and social
care through research.
• A platform to debate and shape
research
• Digital experience for patients and
the public
• An end to end digital research
service
• A platform to attract, develop and
retain research professionals
• Data donor: giving patients control
over the data and us access to new
sources
All underpinned by consent and data
security.
46
‘We’ve Got Your Back’ StudyHow the different pieces can fit together
51
Immediately
Transition to
Routine CareQualified
Independent
Research Teams
Digital
Therapeutics
Research
Network
Simplified Study
Setup
4
App Prescribing
Platform &
Research Apps
2
3
DEMO
Panel- Dr Indra Joshi, Clinical Lead, NHS England- Professor Martin Cowie, Professor of Cardiology & Honorary Consultant
Cardiologist, Royal Brompton & Harefield NHS Foundation Trust- Mark Duman, North West Service Champion, Diabetes UK- Mark Campbell, Acting Programme Director, NICE- Dr Mark Kelsey, GP, Clinical Chair, Southampton City CCG- Professor Colin Espie, Co-founder and Chief Medical Officer, Big HealthChaired by:
Stage: Sarah Haywood, CEO, MedCity
Floor: Dr Mark Davies, GP, Non Exec Director, BMJ, Chair Clinical Advisory Board, Your.MD
49
Mark Campbell
Closing thoughts
Acting Programme Director –Devices and Diagnostics National Institute for Health and Care Excellence